REGULATION OF FOCAL ADHESION TURNOVER BY ERBB RECEPTOR SIGNALING AND PRECLINICAL IMPLICATIONS FOR ERBB-2+INVASIVE BREAST CANCER MODELS

被引：0
|
作者：
Alaoui-Jamali, Moulay [1 ]
机构：
[1] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst, Segall Comprehens Canc Ctr,Dept Med & Oncol, Montreal, PQ H3T 1E2, Canada
来源：
ANTICANCER RESEARCH | 2008年 / 28卷 / 5C期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8
引用
收藏
页码：3187 / 3188
页数：2
相关论文
共 50 条
  • [31] Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells
    Canfield, Kaleigh
    Li, Jiaqi
    Wilkins, Owen M.
    Morrison, Meghan M.
    Ung, Matthew
    Wells, Wendy
    Williams, Charlotte R.
    Liby, Karen T.
    Vullhorst, Detlef
    Buonanno, Andres
    Hu, Huizhong
    Schiff, Rachel
    Cook, Rebecca S.
    Kurokawa, Manabu
    CELL CYCLE, 2015, 14 (04) : 648 - 655
  • [32] Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
    Grabinski, Nicole
    Ewald, Florian
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1096 - 1104
  • [33] Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
    Nicole Grabinski
    Florian Ewald
    Investigational New Drugs, 2014, 32 : 1096 - 1104
  • [34] The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2+ breast cancer cells
    D'Alesio, Carolina
    Bellese, Grazia
    Gagliani, Maria Cristina
    Lechiara, Anastasia
    Dameri, Martina
    Grasselli, Elena
    Lanfrancone, Luisa
    Cortese, Katia
    Castagnola, Patrizio
    BIOLOGY OPEN, 2019, 8 (04):
  • [35] Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients
    DiGiovanna, MP
    Stern, DF
    Edgerton, SM
    Whalen, SG
    Moore, D
    Thor, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1152 - 1160
  • [36] Reciprocal regulation of NOTCH1 and ErbB2 in breast cancer.
    Osipo, C.
    Patel, P.
    Lupu, R.
    Miele, L.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S245 - S246
  • [37] Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins
    Asp, Nagham
    Kvalvaag, Audun
    Sandvig, Kirsten
    Pust, Sascha
    ONCOTARGET, 2016, 7 (18) : 25443 - 25460
  • [38] AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
    Hickinson, D. Mark
    Klinowska, Teresa
    Speake, Georgina
    Vincent, John
    Trigwell, Cath
    Anderton, Judith
    Beck, Sarah
    Marshall, Gayle
    Davenport, Sara
    Callis, Rowena
    Mills, Elizabeth
    Grosios, Konstantina
    Smith, Paul
    Barlaam, Bernard
    Wilkinson, Robert W.
    Ogilvie, Donald
    CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1159 - 1169
  • [39] Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer
    Marx, Corina
    Yau, Christina
    Banwait, Surita
    Zhou, Yamei
    Scott, Gary K.
    Hann, Byron
    Park, John W.
    Benz, Christopher C.
    MOLECULAR PHARMACOLOGY, 2007, 71 (06) : 1525 - 1534
  • [40] ErbB2 immune response in breast cancer patients with soluble receptor ectodomain
    Visco, V
    Bei, R
    Moriconi, E
    Gianni, W
    Kraus, MH
    Muraro, R
    AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (04): : 1417 - 1424
12345